Liposome Drug Delivery Market Scope And Analysis

  • Report Code : TIPRE00010407
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Liposome Drug Delivery Market Analysis Report 2023 to 2031

Buy Now

Liposome Drug Delivery Market Report Liposome Drug Delivery Market Size and Share Liposome Drug Delivery Market Scope and Analysis

Liposome Drug Delivery Market Report Scope

Report Attribute Details
Market size in 2021 US$ 4.2 Billion
Market Size by 2031 US$ 11.5 Billion
Global CAGR (2023 - 2031) 8.3%
Historical Data 2021-2022
Forecast period 2023-2031
Segments Covered By Product
  • Liposomal Doxorubicin
  • Liposomal Paclitaxel
  • Liposomal Amphotericin B
By Technology
  • Stealth Liposome Technology
  • Non-PEGylated Liposome Technology
  • DepoFoam Liposome Technology
  • Lysolipid Thermally Sensitive Liposome
By Application
  • Fungal Diseases
  • Cancer Therapy
  • Pain Management
  • Viral Vaccines
  • Photodynamic Therapy
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Takeda Pharmaceutical Company Limited
  • Novartis
  • Luye Pharma Group
  • Ipsen Pharma
  • CELSION Inc
  • Astellas Pharma Inc
  • Johnson Johnson Services Inc
  • Acrotech Biopharma Inc
  • Gilead Sciences Inc
  • Sun Pharmaceuticals

    • Liposome Drug DeliveryMarket News and Recent Developments

    The Liposome Drug DeliveryMarket is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in them market for Liposome Drug Delivery and strategies:

    • In June 2022, Endo Internal Plc's subsidiary company "Endo Ventures Limited (EVL)" and Taiwan Liposome Company, Ltd. (TLC) announced collaboration to commercialize "TLC599" an investigational product by TLC. Currently, TLC599 is an injectable compound designed to address osteoarthritis knee pain showcasing the continuous efforts to advance treatment options in the therapeutic area.

    Liposome Drug DeliveryMarket Report Coverage and Deliverables

    The “Liposome Drug DeliveryMarket Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

    • Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
    • Market dynamics such as drivers, restraints, and key opportunities
    • Key future trends
    • Detailed PEST/Porter’s Five Forces and SWOT analysis
    • Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
    • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
    • Detailed company profiles